Patients With Medicare Advantage Insurance Plans
Customers
0
None disclosed
Suppliers
1
0 disclosed
Latest period
Sep 30, 2024
10-Q filed 2024-11-06
Suppliers 1
Companies that disclose Patients With Medicare Advantage Insurance Plans as a major customer, as a share of their own revenue. 0 active, 1 lapsed.
| Company | % of their revenue | Est. $ from Patients With Medicare Advantage Insurance Plans | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| MYO MYOMO, INC. |
24% | $2.2M | 3M 2024-09-30 | −2.0pp | Lapsed Last seen 2024-09-30 |
10-Q 2024-11-06 |
For the three and nine months ended September 30, 2024, approximately 24% and 27% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and six months ended June 30, 2024, approximately 26% and 30% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the year ended December 31, 2023, approximately 57% of our product revenues were derived from patients with Medicare Advantage insurance plans. For the three and nine months ended September 30, 2023, approximately 59% and 59% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and six months ended June 30, 2023, approximately 63% and 59% of the Company's product revenues were derived from patients with Medicare advantage insurance plans, respectively. For the three months ended March 31, 2024 and 2023, approximately 38% and 53% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the year ended December 31, 2023 and 2022, approximately 57% and 60% of the Companys product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and nine months ended September 30, 2022, approximately 62% and 62% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and six months ended June 30, 2022, approximately 71% and 63% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the year ended December 31, 2022 and 2021, approximately 60% and 59% of the Company's product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and nine months ended September 30, 2021, approximately 71% and 62% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and six months ended June 30, 2021, approximately 52% and 54% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three months ended March 31, 2022 and 2021, approximately 52% and 56% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the year ended December 31, 2021 and 2020, approximately 59% and 50% of our revenues were derived from patients with Medicare Advantage insurance plans, respectively. | ||||||
Alerts are coming
Get an email when Patients With Medicare Advantage Insurance Plans's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.